158 related articles for article (PubMed ID: 12183236)
1. Effect of 5-iodo-2'-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice.
Neyts J; Verbeken E; De Clercq E
Antimicrob Agents Chemother; 2002 Sep; 46(9):2842-7. PubMed ID: 12183236
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine for treatment of vaccinia virus (orthopoxvirus) infections in mice.
Neyts J; De Clercq E
Antimicrob Agents Chemother; 2001 Jan; 45(1):84-7. PubMed ID: 11120949
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice.
Neyts J; De Clercq E
J Med Virol; 1993 Nov; 41(3):242-6. PubMed ID: 8263505
[TBL] [Abstract][Full Text] [Related]
4. Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection.
Shearer JD; Siemann L; Gerkovich M; House RV
Antimicrob Agents Chemother; 2005 Jul; 49(7):2634-41. PubMed ID: 15980330
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice.
Quenelle DC; Collins DJ; Kern ER
Antimicrob Agents Chemother; 2003 Oct; 47(10):3275-80. PubMed ID: 14506041
[TBL] [Abstract][Full Text] [Related]
6. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice.
Smee DF; Bailey KW; Wong MH; Sidwell RW
Antiviral Res; 2001 Oct; 52(1):55-62. PubMed ID: 11530188
[TBL] [Abstract][Full Text] [Related]
7. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.
Yang G; Pevear DC; Davies MH; Collett MS; Bailey T; Rippen S; Barone L; Burns C; Rhodes G; Tohan S; Huggins JW; Baker RO; Buller RL; Touchette E; Waller K; Schriewer J; Neyts J; DeClercq E; Jones K; Hruby D; Jordan R
J Virol; 2005 Oct; 79(20):13139-49. PubMed ID: 16189015
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus E3 14.7-kilodalton protein, an antagonist of tumor necrosis factor cytolysis, increases the virulence of vaccinia virus in severe combined immunodeficient mice.
Tufariello JM; Cho S; Horwitz MS
Proc Natl Acad Sci U S A; 1994 Nov; 91(23):10987-91. PubMed ID: 7971996
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of N-methanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of vaccinia virus.
Smee DF; Hurst BL; Wong MH; Glazer RI; Rahman A; Sidwell RW
Antiviral Res; 2007 Nov; 76(2):124-9. PubMed ID: 17658623
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia.
Neyts J; Leyssen P; Verbeken E; De Clercq E
Antimicrob Agents Chemother; 2004 Jun; 48(6):2267-73. PubMed ID: 15155231
[TBL] [Abstract][Full Text] [Related]
11. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir.
Smee DF; Bailey KW; Sidwell RW
Antivir Chem Chemother; 2001 Jan; 12(1):71-6. PubMed ID: 11437324
[TBL] [Abstract][Full Text] [Related]
12. Target-organ treatment of neurotropic virus diseases: efficacy as a chemotherapy tool and comparison of activity of adenine arabinoside, cytosine arabinoside, idoxuridine, and trifluorothymidine.
Allen LB; Sidwell RW
Antimicrob Agents Chemother; 1972 Sep; 2(3):229-33. PubMed ID: 4790562
[TBL] [Abstract][Full Text] [Related]
13. Antiviral activities and phosphorylation of 5-halo-2'-deoxyuridines and N-methanocarbathymidine in cells infected with vaccinia virus.
Smee DF; Humphreys DE; Hurst BL; Barnard DL
Antivir Chem Chemother; 2008; 19(1):15-24. PubMed ID: 18610554
[TBL] [Abstract][Full Text] [Related]
14. Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice.
Smee DF; Wong MH; Bailey KW; Beadle JR; Hostetler KY; Sidwell RW
Int J Antimicrob Agents; 2004 May; 23(5):430-7. PubMed ID: 15120719
[TBL] [Abstract][Full Text] [Related]
15. Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections.
Kern ER; Prichard MN; Quenelle DC; Keith KA; Tiwari KN; Maddry JA; Secrist JA
Antimicrob Agents Chemother; 2009 Feb; 53(2):572-9. PubMed ID: 19029322
[TBL] [Abstract][Full Text] [Related]
16. Effect of cytosine, arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus.
De Clercq E; Luczak M; Shugar D; Torrence PF; Waters JA; Witkop B
Proc Soc Exp Biol Med; 1976 Mar; 151(3):487-90. PubMed ID: 1257248
[TBL] [Abstract][Full Text] [Related]
17. Vaccinia virus lacking the deoxyuridine triphosphatase gene (F2L) replicates well in vitro and in vivo, but is hypersensitive to the antiviral drug (N)-methanocarbathymidine.
Prichard MN; Kern ER; Quenelle DC; Keith KA; Moyer RW; Turner PC
Virol J; 2008 Mar; 5():39. PubMed ID: 18321387
[TBL] [Abstract][Full Text] [Related]
18. Wiskott-Aldrich syndrome protein is needed for vaccinia virus pathogenesis.
Guerra S; Aracil M; Conde R; Bernad A; Esteban M
J Virol; 2005 Feb; 79(4):2133-40. PubMed ID: 15681416
[TBL] [Abstract][Full Text] [Related]
19. Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus.
Zaitseva M; McCullough KT; Cruz S; Thomas A; Diaz CG; Keilholz L; Grossi IM; Trost LC; Golding H
J Virol; 2015 Mar; 89(6):3295-307. PubMed ID: 25589648
[TBL] [Abstract][Full Text] [Related]
20. Cell line dependency for antiviral activity and in vivo efficacy of N-methanocarbathymidine against orthopoxvirus infections in mice.
Smee DF; Wandersee MK; Bailey KW; Wong MH; Chu CK; Gadthula S; Sidwell RW
Antiviral Res; 2007 Jan; 73(1):69-77. PubMed ID: 16712967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
